3Mohammed KA, Nasreen N, Hardwick J, et al. Bacterial induction of pleural mesothelial monolayer barrier dysfunction [ J ]. Am J Physiol Lung Cell Mol Physiol, 2001,281 ( 1 ) : 119-125.
4Kasahara K, Shibata K, Shintani H, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer [ J ]. Anticancer Res, 2006,26 (2B) :1495-1499.
5Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action [J]. Exp Cell Res, 2006,312(5) :594-607.
6Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine[J]. Anticancer Drugs, 2005,16(5) :551-557.
7Kesterson JP, Mhawech-Fauceglia P, Lele S.The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report [J]. Gynecol Oncol, 2008, 111 (3): 527-9.
8Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin [J]. FASEB J, 2001,15 (6): 1044-53.
9Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment [J]. Crit Rev Ther Drug Carrier Syst, 2007, 24 (5): 445-92.
10Velde EA, Reijerkerk A, Brandsma D, et al. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells [J]. Br J Cancer, 2005, 92(4): 729-35.
